Figure 3From: Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximabEvolution of circulating myeloid and plasmacytoid dendritic cell counts over 14-week treatment with infliximab. Evolution of circulating myeloid dendritic cell (mDC) and plasmacytoid dendritic cell (pDC) counts over a 14-week period of treatment with infliximab in (a) responder patients (n = 46) and (b) nonresponder patients (n = 13). Squares indicate matched samples. *P < 0.05, using Wilcoxon matched-pairs test.Back to article page